DIABETES IMMUNE MONITORING CORE (DIMC): PROJECT SUMMARY/ABSTRACT The specialized expertise of the Diabetes Immune Monitoring Core (DIMC) successfully provides SDRC investigators with the capacity to perform modern molecular, cellular and functional studies of human immune cells in type 1 (T1D), type 2 (T2D) and type 3c (T3cD) diabetes. Many SDRC members perform collaborative studies of immuno-biology in physiological or pathological settings, including transplant tolerance, inflammation, cell signaling, immune cell metabolism, immunogenic vs non-immunogenic cell death, genetics, epigenetics, islet immunology and immune therapy. A key feature of the DIMC is our direct focus on human immunology with the assessment of leukocytes in blood and tissues. An essential component is the provision of validated and standardized high dimensional instrumentation, reagents and assays to probe B, NK, T, myeloid and granulocytic cell lineages in blood and tissue from patients with or at-risk for diabetes. These robust tools have increased the number of SDRC investigators studying human diabetes at Stanford. In addition, the DIMC has evolved to meet the emerging interests of SDRC investigators by developing human tissue procurement for immuno-biology studies related to diabetes, including archiving of fractionated blood cells and serum from subjects with new-onset T1D, and isolation and banking of matched bone marrow/hematopoietic stem cells in coordination with the SDRC Islet Research Core. These activities are not provided by any other research core to diabetes researchers at Stanford. The DIMC’s current support also enhances the emerging Stanford Pancreatic Islet Replacement and Immune Tolerance (SPIRIT) human islet transplantation program for Stanford Health Care (SHC) patients with T3cD and eventually T1D. The DIMC also provides training for investigators in specialized methods of human Immunology such as CyTOF, high dimensional flow cytometry, cytokine/chemokine microbead arrays, mixed lymphocyte reactions, T cell receptor repertoire analysis via RNASeq and monitoring of B, T and APC responses to ß cells and their antigens. DIMC personnel will continue to work closely with SDRC investigators to build efficient experimental strategies tailored to their needs. This support will help investigators develop the new clinical programs at SHC. Integration of DIMC efforts with other SDRC research cores will continue to enrich and enhance studies of human immune cells relevant to diabetes. The DIMC evolves to serve the SDRC community by continuously developing new experimental capacity to match an explosion in sophisticated technologies. The DIMC will also serve SDRC members at the Universities of California at Berkeley or at Davis, including those supported through the proposed Regional Pilot & Feasibility Award expansion. Based on growth of the SDRC membership, evolution of exciting new services, increasing membership demand for human immune and hematopoietic stem c...